Literature DB >> 19789839

The particular relationship between Parkinson's disease and malignancy: a focus on skin cancers.

Rivka Inzelberg1, Simon D Israeli-Korn.   

Abstract

Although the risk for most cancers appears to be relatively low in patients with Parkinson's disease (PD), skin cancers and melanomas occur more frequently in the PD population as compared to controls. This article summarizes the findings of cohort studies on skin cancer in Parkinson's disease. Given that melanoma may precede use of L-dopa, the increased risk of melanoma for PD patients cannot be attributed to L-dopa. On the basis of these observations it may be reasonable to recommend that all patients with PD, whether treated with L-dopa or not, should undergo regular dermatological screening for neoplastic or pre-neoplastic skin lesions, especially melanoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19789839     DOI: 10.1007/s00702-009-0322-x

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  43 in total

1.  Problem situations in the treatment of paralysis agitans.

Authors:  L J DOSHAY
Journal:  J Am Med Assoc       Date:  1954-10-16

2.  Malignant melanoma in early Parkinson's disease: the DATATOP trial.

Authors:  Radu Constantinescu; Megan Romer; Karl Kieburtz
Journal:  Mov Disord       Date:  2007-04-15       Impact factor: 10.338

3.  Occurrence of different cancers in patients with Parkinson's disease.

Authors:  H Møller; L Mellemkjaer; J K McLaughlin; J H Olsen
Journal:  BMJ       Date:  1995-06-10

4.  Low cancer rates among patients with Parkinson's disease.

Authors:  B Jansson; J Jankovic
Journal:  Ann Neurol       Date:  1985-05       Impact factor: 10.422

5.  Levodopa and melanoma: three cases and review of literature.

Authors:  F H Rampen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-06       Impact factor: 10.154

6.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

Review 7.  Levodopa therapy and the risk of malignant melanoma.

Authors:  J F Siple; D C Schneider; W A Wanlass; B K Rosenblatt
Journal:  Ann Pharmacother       Date:  2000-03       Impact factor: 3.154

Review 8.  Melanoma, Parkinson's disease and levodopa: causal or spurious link? A review of the literature.

Authors:  Roberto Zanetti; Dora Loria; Stefano Rosso
Journal:  Melanoma Res       Date:  2006-06       Impact factor: 3.599

9.  Genetic analysis of LRRK2 mutations in patients with Parkinson disease.

Authors:  Hao Deng; WeiDong Le; Yi Guo; Christine B Hunter; WenJie Xie; MaoSheng Huang; Joseph Jankovic
Journal:  J Neurol Sci       Date:  2006-11-09       Impact factor: 3.181

10.  A prospective cohort study of cancer incidence following the diagnosis of Parkinson's disease.

Authors:  Jane A Driver; Giancarlo Logroscino; Julie E Buring; J Michael Gaziano; Tobias Kurth
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-06       Impact factor: 4.254

View more
  9 in total

Review 1.  Meta-analysis of the relationship between Parkinson disease and melanoma.

Authors:  Rui Liu; Xiang Gao; Yi Lu; Honglei Chen
Journal:  Neurology       Date:  2011-06-07       Impact factor: 9.910

2.  The role of alpha-synuclein in melanin synthesis in melanoma and dopaminergic neuronal cells.

Authors:  Tianhong Pan; Julie Zhu; Wen-Jen Hwu; Joseph Jankovic
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

Review 3.  Cancer and neurodegeneration: between the devil and the deep blue sea.

Authors:  Hélène Plun-Favreau; Patrick A Lewis; John Hardy; L Miguel Martins; Nicholas W Wood
Journal:  PLoS Genet       Date:  2010-12-23       Impact factor: 5.917

Review 4.  Diametrical diseases reflect evolutionary-genetic tradeoffs: Evidence from psychiatry, neurology, rheumatology, oncology and immunology.

Authors:  Bernard J Crespi; Matthew C Go
Journal:  Evol Med Public Health       Date:  2015-09-09

5.  Looking beyond the brain to improve the pathogenic understanding of Parkinson's disease: implications of whole transcriptome profiling of Patients' skin.

Authors:  Anu Planken; Lille Kurvits; Ene Reimann; Liis Kadastik-Eerme; Külli Kingo; Sulev Kõks; Pille Taba
Journal:  BMC Neurol       Date:  2017-01-10       Impact factor: 2.474

Review 6.  Biological and Clinical Implications of Comorbidities in Parkinson's Disease.

Authors:  Jose A Santiago; Virginie Bottero; Judith A Potashkin
Journal:  Front Aging Neurosci       Date:  2017-12-04       Impact factor: 5.750

7.  Accumulation of minor alleles and risk prediction in schizophrenia.

Authors:  Pei He; Xiaoyun Lei; Dejian Yuan; Zuobin Zhu; Shi Huang
Journal:  Sci Rep       Date:  2017-09-15       Impact factor: 4.379

8.  Carbidopa, an activator of aryl hydrocarbon receptor, suppresses IDO1 expression in pancreatic cancer and decreases tumor growth.

Authors:  Ksenija Korac; Devaraja Rajasekaran; Tyler Sniegowski; Bradley K Schniers; Andrew F Ibrahim; Yangzom D Bhutia
Journal:  Biochem J       Date:  2022-09-16       Impact factor: 3.766

9.  Susceptibility loci for pigmentation and melanoma in relation to Parkinson's disease.

Authors:  Jing Dong; Jianjun Gao; Michael Nalls; Xiang Gao; Xuemei Huang; Jiali Han; Andrew B Singleton; Honglei Chen
Journal:  Neurobiol Aging       Date:  2013-12-27       Impact factor: 4.673

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.